{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T11:53:07Z","timestamp":1662465187516},"reference-count":0,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[1996,1]]},"DOI":"10.2165\/00019053-199609010-00007","type":"journal-article","created":{"date-parts":[[2009,3,5]],"date-time":"2009-03-05T00:40:03Z","timestamp":1236213603000},"page":"61-75","source":"Crossref","is-referenced-by-count":12,"title":["Switching the Histamine H2 Receptor Antagonist Famotidine to Nonprescription Status in Canada"],"prefix":"10.1007","volume":"9","author":[{"given":"Rachel F.","family":"Tasch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron","family":"Goeree","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Curtis J.","family":"Henke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernie J.","family":"O\u02bcBrien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","container-title":["PharmacoEconomics"],"original-title":[],"language":"en","deposited":{"date-parts":[[2013,1,20]],"date-time":"2013-01-20T14:37:18Z","timestamp":1358692638000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.2165\/00019053-199609010-00007"}},"subtitle":["An Economic Evaluation"],"short-title":[],"issued":{"date-parts":[[1996,1]]},"references-count":0,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.2165\/00019053-199609010-00007","relation":{},"ISSN":["1170-7690"],"issn-type":[{"value":"1170-7690","type":"print"}],"subject":[],"published":{"date-parts":[[1996,1]]}}}